BiotechTube

YM443

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dyspepsia

Conditions

Dyspepsia, Functional Dyspepsia

Trial Timeline

Aug 1, 2008 → Dec 1, 2009

NCT ID
NCT00764374

About YM443

YM443 is a phase 3 stage product being developed by Astellas Pharma for Dyspepsia. The current trial status is completed. This product is registered under clinical trial identifier NCT00764374. Target conditions include Dyspepsia, Functional Dyspepsia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT00764374Phase 3Completed
NCT00102310Phase 2Completed

Competing Products

20 competing products in Dyspepsia

See all competitors
ProductCompanyStageHype Score
YH12852 0.1 mg + YH12852 0.25 mg + YH12852 0.5 mg + PlaceboYuhanPhase 2
52
YM443 + Placebo + MoxifloxacinAstellas PharmaPhase 1
33
Cinitapride + domperidoneEisaiPhase 3
77
Rabeprazole + Rabeprazole + Rabeprazole + PlaceboEisaiPhase 2
52
Z-338Zeria PharmaceuticalPhase 3
76
Imonogas + EspumisanJohnson & JohnsonPhase 3
77
esomeprazoleAstraZenecaApproved
85
Esomeprazole MagnesiumAstraZenecaApproved
85
TegaserodNovartisPhase 3
77
TegaserodNovartisPhase 3
77
TegaserodNovartisPhase 3
77
Tegaserod and PlaceboNovartisApproved
85
TegaserodNovartisPhase 3
77
TegaserodNovartisPhase 3
77
Gabapentin + PlaceboPfizerPhase 3
76
Z-338Zeria PharmaceuticalPhase 2
51
Z-338Zeria PharmaceuticalPhase 2
51
Z-338Zeria PharmaceuticalPhase 2
51
Z-338 + PlaceboZeria PharmaceuticalPhase 3
76
Acotiamide hydrochloride hydrate + PlaceboZeria PharmaceuticalPhase 3
76

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85